In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with David Leitham, Senior Vice President and General Manager at Aspen Technology.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:
Why a transformative approach is now needed to better deal with new therapeutics and modalities.
The pandemic as the inflexion point for companies in pharma to truly adapt technology and create a competitive advantage.
How contract services organisations are driving change in the life science sector and why they could be the ‘lighthouse’ for others to follow.
Being open to failure, embracing the wrong calls and treating every set back as a learning opportunity.
David leads the pharma business unit at AspenTech, defining solutions that best serve the needs of pharmaceutical manufacturers to accelerate digitalization in their environments.
Prior to AspenTech, David spent nearly 20 years with Thermo Fisher Scientific.
He held multiple leadership positions, most recently as Vice President and General Manager responsible for a team of more than 500 people. In this role, he drove digital transformation efforts for multiple businesses within the company, while also integrating and harmonising product divisions for improved organisation and performance.
His previous roles include Glaxo SmithKline where he served as Vice President, Information Engineering, Technology and Architecture. David attended Penn State University where he holds a Master of Science degree in Software Engineering, and a Bachelor of Science degree in Aerospace Engineering.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.